News AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.
News CapstanTx secures $165 million to deliver precise in vivo ce... Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo
Digital Asking the right questions around AI, with Brian Alexander, ... At BIO 2025, editor-in-chief Jonah Comstock spoke with Brian Alexander, CEO of Valo Health, about how he’s seeing the AI conversation evolve.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
